HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has scheduled a conference call for Thursday, Nov. 12, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended Sept. 30, 2026. The announcement is significant because it provides investors and stakeholders with a formal opportunity to hear directly from management about the company's recent progress, particularly the results from the ALIGN-ACS pilot study, and to outline upcoming milestones for its Heart Attack Detection program. These updates could offer critical insights into the company's trajectory in the competitive cardiac monitoring space.
During the call, Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the session, which will include a question-and-answer segment. A press release detailing the quarterly results will be issued before the call. Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through Nov. 26, 2026. For full details, see the full press release.
HeartBeam is developing the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, redefining cardiac health management. The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement.
The upcoming earnings call is particularly important as it will provide a platform for management to elaborate on the ALIGN-ACS pilot study results, which could influence the company's Heart Attack Detection program. Investors will be listening for details on regulatory pathways, potential partnerships, and commercialization strategies. With the recent FDA clearances, HeartBeam is positioning itself at the forefront of portable cardiac diagnostics, and the call may shed light on how quickly the company can move toward market adoption.
For ongoing updates, the latest news and information relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. Detailed information on the cleared indications for use can be found at https://www.heartbeam.com/indications. The announcement was distributed through MissionIR, a communications platform that is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services.
